The Baupost Group
31
222M
24
0.74
7
0.23
12
- Areas of investment
Summary
In 1982 was created The Baupost Group, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the Boston.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the The Baupost Group, startups are often financed by Omega Funds, SR One, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Omega Funds, Fidelity Management and Research Company, SR One. In the next rounds fund is usually obtained by Omega Funds, Fidelity Management and Research Company, Silicon Valley Bank.
The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 deals per year. Comparing to the other companies, this The Baupost Group performs on 28 percentage points more the average number of lead investments. The top activity for fund was in 2014. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2019. The average startup value when the investment from The Baupost Group is more than 1 billion dollars.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Intarcia Therapeutics, Idenix Pharmaceuticals, Gossamer Bio. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Personal Health, Biotechnology.
We also calculated 7 valuable employees in our database.
Investments analytics
Analytics
- Total investments
- 31
- Lead investments
- 7
- Exits
- 12
- Rounds per year
- 0.74
- Follow on index
- 0.23
- Investments by industry
- Biotechnology (17)
- Health Care (11)
- Pharmaceutical (6)
- Health Diagnostics (6)
- Therapeutics (5) Show 47 more
- Investments by region
-
- United States (24)
- Israel (1)
- The Netherlands (1)
- Germany (1)
- United Kingdom (2) Show 1 more
- Peak activity year
- 2021
- Number of Unicorns
- 6
- Number of Decacorns
- 6
- Number of Minotaurs
- 6
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 886M
- Group Appearance index
- 0.77
- Avg. company exit year
- 16
- Avg. multiplicator
- 0.19
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cullinan Oncology | 17 Dec 2020 | Biotechnology, Medical Device, Biopharma | Late Stage Venture | 131M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.